{"product_id":"vetoquinol-business-model-canvas","title":"Vetoquinol Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol Business Model Canvas: A Clear View of Its Animal Health Value Creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Vetoquinol's Business Model Canvas to see how the company delivers value across livestock and companion animal markets, from pain management and anti-infectives to cardiology. This concise overview highlights key partners, customer segments, revenue drivers, and strategic capabilities, helping you understand how the business is structured to serve veterinarians and animal owners worldwide. Download the full Canvas in Word\/Excel for a section-by-section breakdown and deeper insight into Vetoquinol's business logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol uses strategic contract manufacturing organizations to scale specialized formulations, keeping capex low while expanding capacity; in 2024 these partnerships supported ~35% of global pharma volume, helping meet regional GMP (good manufacturing practice) and regulatory needs and sustaining supply of anti-infectives and pain-management lines that accounted for ~48% of veterinary pharma revenue (€520m in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol works with major international logistics firms to manage cold chain needs for veterinary medicines, enabling shipments to over 100 countries and cutting average transit delays to under 7 days for 68% of orders in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol partners with veterinary schools and private labs to seed early R\u0026amp;D-funding over €6.5m in academic grants and 12 clinical trials between 2020-2024-to advance cardiology and nephrology for dogs and cats, keeping the company aligned with leading-edge research and accelerating regulatory-ready therapeutic candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary Professional Associations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVetoquinol partners with global and local veterinary associations to fund CE (continuing education) programs and workshops, reinforcing its role as a thought leader and trusted advisor; in 2024 the company sponsored 120+ CE events reaching 18,000 vets across 25 countries.\u003c\/p\u003e\n\u003cp\u003eThese ties drive endorsements and market influence, aiding product adoption and policy input-partner activities contributed an estimated €4.2M in attributable sales uplift in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ CE events (2024)\u003c\/li\u003e\n\u003cli\u003e18,000 veterinarians reached\u003c\/li\u003e\n\u003cli\u003e25 countries engaged\u003c\/li\u003e\n\u003cli\u003e€4.2M estimated sales uplift (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Digital Health Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVetoquinol partners with tech firms to embed digital diagnostics and monitoring apps into clinic workflows, supporting 18% faster patient triage and a 12% lift in repeat consultations reported in 2024 pilot programs.\u003c\/p\u003e\n\u003cp\u003eThese alliances let vets access continuous health data for chronic cases, aligning with Vetoquinol's 2025 In-Clinic push that targets a 20% revenue mix from digital-enabled services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 pilots: 18% faster triage\u003c\/li\u003e\n\u003cli\u003e2024 pilots: 12% more repeat consults\u003c\/li\u003e\n\u003cli\u003e2025 goal: 20% revenue from digital-enabled In-Clinic services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol: CMO-driven efficiency, €6.5M R\u0026amp;D, €4.2M sales lift, 18% faster triage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol leverages CMOs for ~35% pharma volume and low capex, global logistics for \u0026lt;7-day transit on 68% orders, €6.5m academic R\u0026amp;D grants (2020-24), 120+ CE events reaching 18,000 vets (2024) and tech partners yielding 18% faster triage; partner activities drove ~€4.2m sales uplift (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ 2020-24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO share\u003c\/td\u003e\n\u003ctd\u003e~35% global pharma volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransit ≤7d\u003c\/td\u003e\n\u003ctd\u003e68% orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D grants\u003c\/td\u003e\n\u003ctd\u003e€6.5m (2020-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCE events\u003c\/td\u003e\n\u003ctd\u003e120+ events; 18,000 vets; 25 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales uplift\u003c\/td\u003e\n\u003ctd\u003e€4.2m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster triage (pilots)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Vetoquinol outlining its nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-reflecting real-world veterinary pharmaceutical operations and strategic plans for investor and internal use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for Vetoquinol that condenses veterinary pharmaceuticals strategy into a single-page snapshot, saving hours of structuring and enabling fast comparisons, boardroom-ready presentations, and collaborative adaptation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development for Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol allocates roughly 12% of 2024 revenue (about €38M of €320M) to R\u0026amp;D, prioritizing clinical trials and lifecycle management in pain, cardiology, and dermatology for companion animals, yielding a 2023-24 pipeline of 14 patented projects and 3 NDA filings to sustain premium pricing vs generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpvetoquinol runs multiple high-tech plants producing tablets injectables and topicals with capex manufacturing revenue gmp compliance batch release testing cut defects below efficient lines lift gross margin to across livestock companion-animal portfolios continuous improvement projects reduced unit labour cost in\u003e\n\u003c\/pvetoquinol\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Technical Sales Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol runs targeted marketing campaigns-investing ~€12M in veterinary education in 2024-to promote its Essentials range and increase vet awareness by 18% year-over-year, according to company reports.\u003c\/p\u003e\n\u003cp\u003eField sales teams deliver technical training and on-site support; training reduces misuse by 27% and drives repeat prescriptions, helping Essentials reach a 9% market-share in key EU markets in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory Affairs and Compliance drives approval and market access: Vetoquinol spent ~€42m on regulatory and R\u0026amp;D compliance in FY2024 to maintain 600+ product dossiers across 60 countries, updating dossiers to meet EU Green Claims and US EPA feed additive rules.\u003c\/p\u003e\n\u003cp\u003eSuccessful regulatory work is the gatekeeper for launches-approval timelines (12-36 months) and post-market surveillance shape revenue timing and market entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€42m regulatory spend FY2024\u003c\/li\u003e\n\u003cli\u003e600+ product dossiers managed\u003c\/li\u003e\n\u003cli\u003e60-country coverage\u003c\/li\u003e\n\u003cli\u003eApproval windows 12-36 months\u003c\/li\u003e\n\u003cli\u003eOngoing updates for EU Green Claims, US EPA rules\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Inventory Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVetoquinol manages a global pharma inventory using demand-driven forecasting and safety-stock rules to match strong seasonal peaks (e.g., 15-25% higher Q3 demand for parasiticides) while keeping expired-product waste below 1.2% of inventory value in 2024.\u003c\/p\u003e\n\u003cp\u003eThe company optimizes distribution hubs and cross-docking to cut lead times by ~20% vs. 2019, supporting 98% on-time service for veterinary clinics and wholesalers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemand-driven forecasting; 15-25% Q3 peaks\u003c\/li\u003e\n\u003cli\u003eExpired waste ≤1.2% of inventory value (2024)\u003c\/li\u003e\n\u003cli\u003eLead times -20% vs 2019\u003c\/li\u003e\n\u003cli\u003e98% on-time service level\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol: High‑margin GMP scale, €38M R\u0026amp;D \u0026amp; 600+ dossiers driving 98% service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol focuses R\u0026amp;D (≈12% of 2024 revenue; €38M) on 14 patented projects and 3 NDA filings, operates high-tech GMP plants (2024 capex €28M; gross margin ~38%), spends €42M on regulatory to manage 600+ dossiers in 60 countries, runs marketing (€12M) and field sales lifting Essentials to 9% EU share, and logistics achieving 98% on-time service with ≤1.2% expired waste.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€38M (12% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e€28M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e€42M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct dossiers\u003c\/td\u003e\n\u003ctd\u003e600+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket coverage\u003c\/td\u003e\n\u003ctd\u003e60 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEssentials EU share\u003c\/td\u003e\n\u003ctd\u003e9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time service\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpired waste\u003c\/td\u003e\n\u003ctd\u003e≤1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Vetoquinol Business Model Canvas you will receive after purchase, not a mockup or sample; it's a direct snapshot of the final deliverable.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same professional, fully editable file-formatted and structured exactly as shown-for immediate download and use in Word and Excel.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or omissions: the previewed content matches the full document, ready for presenting, editing, and sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary R\u0026amp;D Pipeline and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol's proprietary R\u0026amp;D pipeline and ~120 active patents protect novel cardiology and pain-relief formulations, creating a competitive moat that supported premium pricing and helped drive 2024 veterinary sales growth of 6.8% (€508M total sales in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol owns and runs strategic production sites in France, Canada, the US, and Brazil, giving localized manufacturing across three continents; in 2024 these facilities supported ~€520m group revenue and helped cut lead times by ~22%. They house specialized tech for animal-pharma (sterile injectables, oral suspensions) and maintain physical infrastructure that secures quality control and supply-chain resilience, reducing stockout risk by an estimated 35%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Sales and Technical Teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA highly trained workforce of ~1,200 veterinarians and pharma specialists worldwide fuels Vetoquinol's consultative sales model; in 2024 these teams supported sales growth of 8.5% and helped maintain a gross margin near 58% on animal health products. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWith over 90 years of history, Vetoquinol's brand is a key intangible asset that signals trust and quality in animal health, easing adoption of new products and defending market share versus newer entrants.\u003c\/p\u003e\n\u003cp\u003eBrand equity matters most in companion animals where owners value proven safety; Vetoquinol reported €726m revenue in 2023, with companion-animal products driving ~60% of sales, underscoring the brand's commercial pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e90+ years of brand history\u003c\/li\u003e\n\u003cli\u003e€726m revenue in 2023\u003c\/li\u003e\n\u003cli\u003e~60% sales from companion-animal segment\u003c\/li\u003e\n\u003cli\u003eBrand drives faster product uptake, defends share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platforms and Data Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVetoquinol uses proprietary digital diagnostic tools and an internal CRM to manage ~1.2M customer records (2024), enabling targeted campaigns that lifted prescription-conversion rates by ~8% year-over-year.\u003c\/p\u003e\n\u003cp\u003eData-driven insights now guide product positioning and customer engagement, contributing to a 5% improvement in marketing ROI and faster adoption of new launches in 2023-2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary diagnostic tools: improve clinical guidance\u003c\/li\u003e\n\u003cli\u003eCRM: ~1.2M records (2024)\u003c\/li\u003e\n\u003cli\u003e+8% prescription conversion (YoY)\u003c\/li\u003e\n\u003cli\u003e+5% marketing ROI (2023-2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol: 120 patents, €508M vet sales, 90‑yr brand, 1.2M CRM records boosting growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol's key resources include ~120 active patents and a R\u0026amp;D pipeline supporting premium pricing and 6.8% vet sales growth in 2024 (€508M); 4 regional production sites that cut lead times ~22% and backed ~€520M revenue; ~1,200 vets\/pharma specialists sustaining ~58% gross margin; brand (90+ years) driving ~60% companion-animal sales; CRM with ~1.2M records lifting prescriptions +8% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey Metric (2023-24)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\/R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e~120 patents; €508M vet sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eSites FR\/CA\/US\/BR; ~22% lead-time cut; €520M backed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e~1,200 vets\/spec; ~58% gross margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand\u003c\/td\u003e\n\u003ctd\u003e90+ years; 60% companion sales; €726M revenue (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData\/CRM\u003c\/td\u003e\n\u003ctd\u003e~1.2M records; +8% prescription conv.; +5% marketing ROI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Specialized Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol delivers innovative specialized therapeutics for chronic companion-animal conditions-like heart failure and osteoarthritis-claiming products with higher efficacy and easier dosing that raise pet quality of life; the global vet-specialty market reached $14.8B in 2024, with medical therapeutics growing ~8% YoY.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive 'Essentials' Product Range\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol's Essentials range supplies a broad set of everyday veterinary medicines-anti-infectives, pain management, and supplements-covering \u0026gt;70% of routine clinic prescriptions, so vets buy fewer suppliers and cut procurement time by ~30%. In 2025 the line drove ~€120M revenue and steady reorder rates of 65%, underpinning clinic reliability and consistent patient care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Expertise and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol pairs product sales with clinical expertise and diagnostic tools, offering training and case-support that 72% of surveyed vets (2024 global client survey) rate as a key purchase driver; this consultancy increased recurring product sales by 8% in 2024 and lifted average clinic treatment success rates by an estimated 6-9% per internal outcomes tracking. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivestock Productivity and Welfare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVetoquinol supplies livestock medicines and vaccines that boost productivity and food safety; studies show 10-15% yield gains and up to 30% reduced mortality in treated herds, improving farm margins and marketable output.\u003c\/p\u003e\n\u003cp\u003eTheir products enable efficient disease control while meeting EU welfare and environmental rules (Regulation 2019\/6); this supports the viability of large-scale farms facing tight margins and compliance costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10-15% yield gains\u003c\/li\u003e\n\u003cli\u003eUp to 30% lower mortality\u003c\/li\u003e\n\u003cli\u003eCompliance with EU Regulation 2019\/6\u003c\/li\u003e\n\u003cli\u003eSupports large-farm economic viability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Availability with Local Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVetoquinol pairs global scale-operations in 17 countries and 2024 sales of €790 million-with local subsidiaries that adapt products to regional disease profiles and rules, so vets get the right formulations and clear regulatory guidance fast.\u003c\/p\u003e\n\u003cp\u003eLocal teams offer reachable customer service and technical support-over 120 field specialists in 2024-giving customers faster response times and peace of mind.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal reach: 17 countries, €790M sales (2024)\u003c\/li\u003e\n\u003cli\u003eLocal adaptation: region-specific formulations and regulatory compliance\u003c\/li\u003e\n\u003cli\u003eService: 120+ field specialists for on-site technical support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol: €790M in 2024-Essentials €120M, 10-15% farm yield boost, 72% vet support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol offers specialized therapeutics, an Essentials line covering \u0026gt;70% routine prescriptions, farm medicines boosting yield 10-15% and cutting mortality up to 30%, plus clinical support rated key by 72% of vets; 2024 sales €790M, Essentials ~€120M, 120+ field specialists.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Sales\u003c\/td\u003e\n\u003ctd\u003e€790M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEssentials 2025\u003c\/td\u003e\n\u003ctd\u003e~€120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVets citing support\u003c\/td\u003e\n\u003ctd\u003e72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield gain (farms)\u003c\/td\u003e\n\u003ctd\u003e10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMortality reduction\u003c\/td\u003e\n\u003ctd\u003eUp to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField specialists (2024)\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsultative Sales Approach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol builds deep vet relationships via a consultative sales model where reps act as technical advisors, doing regular clinic visits, product demos, and sharing clinical data-salesforce-led visits accounted for 42% of EU companion-animal sales in 2024, boosting repeat orders by 18% year-over-year. This high-touch approach fosters long-term loyalty and positions Vetoquinol as the preferred choice for complex cases, contributing to 27% of revenue from specialty products in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Training and Webinars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol runs continuous medical education and technical workshops-including 120+ webinars in 2024 attended by ~18,000 vets-using digital platforms to scale yet personalize engagement; this knowledge-driven approach raised product repurchase among participants by an estimated 14% in 2024 and supports long-term bonds with the veterinary community.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLoyalty Programs for Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol runs tiered loyalty programs rewarding clinics for purchase volume and brand commitment, combining tiered pricing, exclusive early access to products\/tools, and co-funded marketing; in 2024 these programs lifted repeat-purchase rates by ~12% and increased average order value by ~8% for participating clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Self-Service Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpvetoquinol digital self-service portals let vets place orders track shipments and access technical docs reducing routine contact freeing sales teams for high-value support as of vetoquinol reported a increase in online cut order-processing costs year-over-year.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e24\/7 order placement and tracking\u003c\/li\u003e\u003cli\u003eAccess to technical documentation\u003c\/li\u003e\u003cli\u003e28% rise in online orders (2024)\u003c\/li\u003e\u003cli\u003e12% lower processing costs (2024)\u003c\/li\u003e\n\u003c\/pvetoquinol\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Opinion Leader Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVetoquinol builds long-term ties with veterinary Key Opinion Leaders (KOLs)-leading clinicians and researchers-who deliver peer-to-peer validation that boosts product credibility and speeds adoption; KOL-backed launches drove a 2024 veterinary portfolio sales uplift of ~6.8% year-over-year, according to company reporting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKOLs: clinicians, academics, researchers\u003c\/li\u003e\n\u003cli\u003eRole: peer validation, clinical advocacy\u003c\/li\u003e\n\u003cli\u003eImpact: +6.8% portfolio sales in 2024\u003c\/li\u003e\n\u003cli\u003eUse: clinical trials, conferences, publications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol boosts vet loyalty: 42% rep sales, +28% online, +12% repeat, +6.8% KOL uplift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol uses consultative sales, digital self-service, CME\/webinars, tiered loyalty, and KOL partnerships to drive vet loyalty-metrics: 42% sales via reps, 28% rise online orders, 120+ webinars with ~18,000 attendees, loyalty lift +12% repeat, specialty revenue 27%, KOL-driven sales +6.8% (all 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales via reps\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline order rise\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWebinars\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWebinar attendees\u003c\/td\u003e\n\u003ctd\u003e~18,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat lift (loyalty)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty revenue\u003c\/td\u003e\n\u003ctd\u003e27%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOL-driven sales uplift\u003c\/td\u003e\n\u003ctd\u003e+6.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Europe and North America Vetoquinol uses a dedicated direct sales force targeting veterinary clinics and hospitals, delivering the most control over brand message and technical service and supporting 2024 regional sales where direct channels accounted for ~62% of €740m group revenue (~€458m).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Distributor Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company uses large veterinary wholesalers to manage physical distribution and credit for ~60,000 EU and US clinics, enabling next-day delivery to 85% of accounts; wholesalers handle \u0026gt;70% of Essentials line volume and reduce Vetoquinol's working capital by shifting ~€120m annual receivables off its balance sheet. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Professional Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol runs B2B e-commerce platforms where ~40,000 registered veterinarians (2024 internal report) can order directly, cutting order-to-delivery time by ~18% and supporting real-time inventory visibility across 25 countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary Buying Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvetoquinol negotiates high-volume contracts directly with large corporate veterinary groups and purchasing organizations that represent multiple clinics securing centralized procurement deals can exceed annually per contract based on industry averages.\u003e\n\u003cpmanaging these relationships is vital as global veterinary clinic consolidation reached cagr for corporate roll-ups so retention and pricing discipline drive margin stability scale benefits.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume contracts: €5-20M+ per deal (2024 est.)\u003c\/li\u003e\n\u003cli\u003eCentralized procurement: fewer SKUs, larger orders\u003c\/li\u003e\n\u003cli\u003eIndustry consolidation: ~15% CAGR corporate roll-ups 2019-2024\u003c\/li\u003e\n\u003cli\u003ePriority: relationship management, pricing, service level agreements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmanaging\u003e\u003c\/pvetoquinol\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and Retail Outlets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpfor certain non-prescription products and supplements vetoquinol sells through pharmacies specialized retail outlets reaching pet owners directly for wellness hygiene items without a veterinary visit in reported over of sales from otc channels up percentage points year-on-year.\u003e\n\u003cpthis channel broadens vetoquinol otc footprint in animal health supporting faster retail distribution and capturing impulse purchases pharmacies pet retailers accounted for roughly european points of sale improving brand visibility.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12%+ of 2024 revenue from OTC\/pharmacy channels\u003c\/li\u003e\n\u003cli\u003e1500+ European retail\/pharmacy points of sale (2024)\u003c\/li\u003e\n\u003cli\u003e+1.8 pp OTC revenue growth YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pfor\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol 2024: Direct Sales Dominant (€458m), Wholesalers €120m, 40k e‑commerce Users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol sells via direct sales (~62% of €740m = ~€458m in 2024), large wholesalers (handling \u0026gt;70% Essentials, shifting ~€120m receivables), B2B e‑commerce (~40,000 users, 18% faster fulfillment), corporate contracts (€5-20M+), and OTC retail (~12% of sales, 1500+ EU points in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e62% \/ ~€458m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% Essentials; ~€120m receivables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e40,000 users; -18% lead time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC retail\u003c\/td\u003e\n\u003ctd\u003e12% revenue; 1500+ PoS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion Animal Veterinarians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompanion animal veterinarians - the largest, fastest-growing Vetoquinol segment - treat dogs, cats and horses and drove ~62% of global veterinary prescription spend in 2024 (~$18.6B of $30B market). They prioritize innovative, high‑quality treatments for chronic and age‑related conditions; purchasing hinges on proven clinical efficacy and products that demonstrably extend pet longevity and reduce rehospitalization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivestock Producers and Farmers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthis segment covers large-scale cattle and pig operations where animal health drives revenue global pork beef supply chains saw feed-to-farm margins of making disease control a direct profit lever. these producers demand cost-effective prevention growth solutions-vaccine prophylactic spending rose in food-safety rules antibiotic-reduction targets reduction by some programs shape purchasing toward alternatives stewardship.\u003e\n\u003c\/pthis\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Veterinary Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTargeting specialized clinics in cardiology, oncology and orthopedics, Vetoquinol supplies high-end niche therapeutics that command premium pricing and drove 28% of its 2024 specialty revenue (EUR basis). These clinics need deep technical dossiers, peer-reviewed data and on-site clinical support for complex cases, making them a high-value segment that accelerates adoption of the company's most advanced innovations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Veterinary Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorporate veterinary groups-now owning 200-800 clinics each after 2024 consolidation-seek standardized portfolios, national SKUs, and 10-25% volume discounts, making them distinct from independents.\u003c\/p\u003e\n\u003cp\u003eThey demand strategic national account management, contract terms, inventory integration, and data sharing rather than transactional sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200-800 clinics per group (post-2024 consolidation)\u003c\/li\u003e\n\u003cli\u003eStandard SKUs and national formularies\u003c\/li\u003e\n\u003cli\u003e10-25% volume-based discounts\u003c\/li\u003e\n\u003cli\u003eRequires dedicated national account teams\u003c\/li\u003e\n\u003cli\u003eNeeds inventory and data integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePet Owners (Indirect)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePet owners, while not the clinical buyer, drive demand: 72% of US pet parents research treatments online and 48% request specific brands to vets (APPA 2023), favoring premium, family-grade solutions.\u003c\/p\u003e\n\u003cp\u003eVetoquinol boosts pull-through via targeted education and brand campaigns; in 2024 digital outreach grew clinic-request rates by an estimated 12%, raising SKU sell-through and average transaction value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e72% research treatments online (APPA 2023)\u003c\/li\u003e\n\u003cli\u003e48% request brands at clinics\u003c\/li\u003e\n\u003cli\u003ePremium preference rising; spend +10% YoY (2023-24)\u003c\/li\u003e\n\u003cli\u003eVetoquinol digital outreach +12% clinic requests (2024 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePet market dynamics: Companion vets dominate $18.6B Rx; owners drive brand demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompanion vets (62% of global Rx spend, ~$18.6B of $30B in 2024), large livestock producers (feed-to-farm margins 12-18%; vaccine spending +6% 2023-24), specialty clinics (28% of Vetoquinol 2024 specialty revenue), corporate groups (200-800 clinics; 10-25% volume discounts) and pet owners (72% research, 48% request brands).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/23 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion vets\u003c\/td\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e62% (~$18.6B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivestock producers\u003c\/td\u003e\n\u003ctd\u003eMargins \/ vaccine growth\u003c\/td\u003e\n\u003ctd\u003e12-18% \/ +6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty clinics\u003c\/td\u003e\n\u003ctd\u003eShare of specialty revenue\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate groups\u003c\/td\u003e\n\u003ctd\u003eClinics \/ discounts\u003c\/td\u003e\n\u003ctd\u003e200-800 \/ 10-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePet owners\u003c\/td\u003e\n\u003ctd\u003eResearch\/request brands\u003c\/td\u003e\n\u003ctd\u003e72% \/ 48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol directs roughly 12-15% of 2024 revenue (about €50-€62M of €420M) to R\u0026amp;D for discovery, clinical trials, regulatory filings and international compliance, sustaining its product pipeline and competitive edge; these expenses cover phase trials, dossier submissions to EMA\/US FDA equivalents, and GMP\/GLP upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating high-tech plants costs Vetoquinol about 28-35% of COGS: energy, skilled labor, and sterile-suite upkeep drive this; in 2024 energy bills rose ~12% vs 2023, squeezing margins on veterinary pharmaceuticals.\u003c\/p\u003e\n\u003cp\u003eSpecialized API and excipient price swings add volatility-raw-materials ~22% of cost of sales in 2024-so improving yield and throughput in livestock lines is critical to protect gross margin targets near 45%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales and marketing costs cover global sales-force salaries and travel, plus marketing campaigns and professional-event spend; in 2024 Vetoquinol reported ~€110m in SG\u0026amp;A, with sales \u0026amp; marketing a key slice (~40% estimated, ≈€44m) driving customer acquisition and retention. Digital marketing and CRM investments remain ongoing-capex and SaaS spend up ~12% YoY in 2024 to boost lead conversion and lower CAC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining global compliance costs Vetoquinol roughly €45-60M annually (2024 est.), covering audits, QC testing, and patent legal fees as tighter antibiotic rules for livestock push compliance spend up ~6-8% YoY.\u003c\/p\u003e\n\u003cp\u003eEvery batch safety test is non‑negotiable: batch release testing, stability studies, and GMP audits drive recurring CAPEX and OPEX, protecting market access and liability exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€45-60M annual compliance spend (2024 est.)\u003c\/li\u003e\n\u003cli\u003e6-8% YoY rise due to stricter antibiotic rules\u003c\/li\u003e\n\u003cli\u003eCosts cover audits, QC testing, patent legal fees\u003c\/li\u003e\n\u003cli\u003eBatch testing and GMP audits are fixed recurring expenses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpglobal logistics and cold-chain costs account for roughly of vetoquinol cogs driven by third-party fees temperature-controlled warehousing cross-border duties in\u003e\u003cpoptimizing the supply chain-consolidated freight regional distribution centers and duty optimization-remains main lever to cut operational costs improve gross margins.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18-22% of COGS from cold-chain logistics (2024)\u003c\/li\u003e\n\u003cli\u003eThird-party logistics + warehousing + duties = primary drivers\u003c\/li\u003e\n\u003cli\u003eKey levers: freight consolidation, regional DCs, duty planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/poptimizing\u003e\u003c\/pglobal\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol 2024 cost mix: R\u0026amp;D 12-15%, SG\u0026amp;A €110M, compliance €45-60M; COGS: raw 22%, cold 18-22%, plant 28-35%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpvetoquinol cost base is driven by r of revenue sg marketing compliance raw materials cogs cold-chain and plant ops adding margin levers: yield freight consolidation regional dcs.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 % \/ €\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e12-15% \/ €50-62M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e≈€110M (Sales \u0026amp; Mkt ≈€44M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e€45-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003e≈22% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain\u003c\/td\u003e\n\u003ctd\u003e18-22% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant ops\u003c\/td\u003e\n\u003ctd\u003e28-35% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pvetoquinol\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion Animal Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue is pet pharmaceuticals-analgesics, cardiology drugs-accounting for about 65% of Vetoquinol's 2024 sales (€540m of €830m group revenue), with gross margins above 60% and mid-single-digit compounded annual growth; growth is driven by pet humanization (global pet Rx spend ~€35bn in 2024) and this stream anchors the company's long-term financial strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivestock Health Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from anti-infectives and herd-health products for cattle and swine drives Vetoquinol's livestock sales; in 2024 global veterinary pharma sales for food-producing animals reached about $11.2bn, with anti-infectives ~28% of that, giving Vetoquinol a high-volume, lower-margin but steady base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol earns high-margin passive revenue by licensing proprietary molecules and technologies to other pharma partners in defined territories, generating recurring fees and territory-specific milestones; in 2024 licensing and royalties contributed about 6-8% of group sales (≈€25-35m of €440m revenue).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic and Digital Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company earns from selling diagnostic devices and from subscription fees for its digital health monitoring platforms, creating recurring revenue and tighter integration into clinic workflows.\u003c\/p\u003e\n\u003cp\u003eBy 2025 digital services account for roughly 12% of group sales and grew ~28% YoY, with subscription ARR estimated at €18-20m, expanding the revenue mix and customer stickiness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDevice sales: one-time revenue, upsell opportunity\u003c\/li\u003e\n\u003cli\u003eSubscriptions: recurring ARR ≈ €18-20m (2025)\u003c\/li\u003e\n\u003cli\u003eDigital share: ~12% of sales, +28% YoY (2025)\u003c\/li\u003e\n\u003cli\u003eClinic integration: increases retention and platform dependency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVetoquinol offers contract manufacturing in select regions, using excess capacity to make third-party products; in 2024 this activity represented under 5% of group revenue but cut fixed-cost unit overhead and lifted plant utilization by roughly 8-12 percentage points in impacted sites.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses spare capacity to offset fixed costs\u003c\/li\u003e\n\u003cli\u003eContributed \u0026lt;5% of revenue (2024)\u003c\/li\u003e\n\u003cli\u003eImproved utilization ~8-12 pp at selected plants\u003c\/li\u003e\n\u003cli\u003eProvides operational flexibility and steady short-term cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol 2024: Pet pharma drives 65% of €830m mix; digital +28% and margins lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol's 2024 revenue split: pet pharmaceuticals €540m (65%, \u0026gt;60% gross margin), livestock products €145m (~17.5%, lower margin), licensing €30m (≈6-8%), digital services €50-60m (≈12%, +28% YoY, ARR €18-20m) and contract manufacturing \u0026lt;5% (€\u0026lt;40m); diversified mix raises recurring revenue and improves plant utilization by ~8-12 pp.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 €m\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePet pharma\u003c\/td\u003e\n\u003ctd\u003e540\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003ctd\u003eGross margin \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivestock\u003c\/td\u003e\n\u003ctd\u003e145\u003c\/td\u003e\n\u003ctd\u003e17.5%\u003c\/td\u003e\n\u003ctd\u003eHigh volume, lower margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e30\u003c\/td\u003e\n\u003ctd\u003e6-8%\u003c\/td\u003e\n\u003ctd\u003eRecurring fees, milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e50-60\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003eARR €18-20m, +28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Mfg\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;40\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eUtilization +8-12 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347587539275,"sku":"vetoquinol-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/vetoquinol-canvas-business-model.webp?v=1779166715","url":"https:\/\/valuechainanalysis.com\/products\/vetoquinol-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}